Nomad Foods heads into the post-earnings week with one clear tension: the stock fell sharply after its Q1 print, yet short sellers are cutting exposure at the fastest pace in months.
The earnings reaction was brutal. The Q1 release on May 7-8 sent the stock down roughly 6.7%, landing it at $9.21 — a 24% decline year-to-date and a multi-year low. The drop reflects the concerns baked into the bear case: flat-to-declining organic revenue, gross margins near four-year lows, and persistent cost inflation outpacing pricing power. For a stock already down 6.6% over the past month before the print, there was little cushion.
What makes this week interesting is the short side's response. Rather than pressing the position after a weak earnings print, short sellers have been exiting. Short interest as a percentage of the free float fell to just 1.05% by May 12 — down nearly 10% on the week and down 24% over the past month. Six weeks ago it stood above 1.5%. The borrow market reflects little tension: the cost to borrow is a negligible 0.46%, and availability remains wide. There is no squeeze pressure here, no heated crowding — shorts that had built up through April are simply unwinding. The ORTEX short score of 29.5 is on the lower end of its recent range, reinforcing how modest the short interest story has become.
Options traders are equally non-committal. The put/call ratio is 0.41, essentially flat with its 20-day average of 0.41 and well below its 52-week high of 0.75. With a z-score close to zero, the options market is registering no unusual positioning in either direction. The options setup describes a stock in limbo rather than one where traders are expressing a strong view.
The Street has been grinding targets lower for months, but buy ratings have proved sticky. Deutsche Bank downgraded to Hold in late March, cutting its target from $15 to $10. Barclays trimmed twice — to $13 in early March and again to $12 in April — while keeping an Overweight. BTIG reiterated its Buy yesterday, holding a $15 target despite the stock trading at $9.21. That $15 target looks ambitious at current levels, and the gap between the mean analyst target of $11.09 and the current price implies 20% upside — though the direction of travel on those estimates has been relentlessly south. On valuation, the stock trades at a PE of 5x and an EV/EBITDA of 6.3x, the latter drifting lower through May. The forward yield is 8.4%, ranking in the 91st percentile on ORTEX's dividend score — which is either the best reason to own the stock or a reflection of how much the market has discounted its durability.
The bull case rests on category recovery, a reinforced brand portfolio, and Nomad's position as market leader across key European frozen-food categories. Noam Gottesman, a co-founder, added 1.5 million shares in Q1, bringing his disclosed holding to 3.9 million shares — a signal of insider confidence worth noting. Martin Franklin, the largest disclosed insider holder at 7.8% of shares, also added 500,000 shares earlier in the year. These are the kind of insider moves that at least suggest those closest to the company do not share the market's immediate pessimism.
The key thing to watch now is whether the Q1 miss triggers a fresh round of estimate cuts or whether the Street's EPS momentum score — which ranks at just the 15th percentile on a 90-day basis — begins to stabilise. With no next earnings event yet confirmed, the story for the near term is whether the post-earnings slide finds a buyer.
See the live data behind this article on ORTEX.
Open NOMD on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
